Moonlake Immunotherapeutics Stock Today
| MLTX Stock | USD 40.55 0.00 0.00% |
PerformanceVery Weak
| Odds Of DistressAverage
|
MoonLake Immunotherapeuti is trading at 40.55 as of the 24th of March 2025; that is No Change since the beginning of the trading day. The stock's open price was 40.545. MoonLake Immunotherapeuti has 52 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. The performance scores are derived for the period starting the 24th of December 2024 and ending today, the 24th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 20th of October 2020 | Category Healthcare | Classification Health Care |
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland. Moonlake Immunotherapeuti is traded on NASDAQ Exchange in the United States. The company has 63.28 M outstanding shares of which 8.05 M shares are now shorted by private and institutional investors with about 21.56 trading days to cover. More on MoonLake Immunotherapeutics
Moving together with MoonLake Stock
Moving against MoonLake Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
MoonLake Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Thematic Idea | Pharmaceutical Products (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||
| Old Name | MULTIMATRIX | |||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Pharmaceutical Products, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsMoonLake Immunotherapeuti can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand MoonLake Immunotherapeuti's financial leverage. It provides some insight into what part of MoonLake Immunotherapeuti's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||
MoonLake Immunotherapeutics (MLTX) is traded on NASDAQ Exchange in USA. It is located in Dorfstrasse 29, Zug, Switzerland, 6300 and employs 100 people. MoonLake Immunotherapeuti is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 2.54 B. MoonLake Immunotherapeuti conducts business under Biotechnology sector and is part of Health Care industry. The entity has 63.28 M outstanding shares of which 8.05 M shares are now shorted by private and institutional investors with about 21.56 trading days to cover.
MoonLake Immunotherapeutics currently holds about 92.71 M in cash with (116.59 B) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.51.
Check MoonLake Immunotherapeuti Probability Of Bankruptcy
Ownership AllocationThe majority of MoonLake Immunotherapeuti outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in MoonLake Immunotherapeutics to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in MoonLake Immunotherapeuti. Please pay attention to any change in the institutional holdings of MoonLake Immunotherapeuti as this could imply that something significant has changed or is about to change at the company.
Check MoonLake Ownership Details
MoonLake Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Marshall Wace Asset Management Ltd | 2024-12-31 | 1.2 M | |
| Polar Capital Holdings Plc | 2024-12-31 | 1.1 M | |
| Alliancebernstein L.p. | 2024-12-31 | 1 M | |
| Fred Alger Management, Llc | 2024-12-31 | 673.8 K | |
| Hood River Capital Management Llc | 2024-12-31 | 649.6 K | |
| Nuveen Asset Management, Llc | 2024-12-31 | 595.6 K | |
| Ing Investment Management Llc | 2024-12-31 | 448.9 K | |
| Finepoint Capital Lp | 2024-12-31 | 447.9 K | |
| Camber Capital Management Llc | 2024-12-31 | 441 K | |
| Bvf Inc | 2024-12-31 | 19.8 M | |
| Cormorant Asset Management, Llc | 2024-12-31 | 8.5 M |
MoonLake Immunotherapeuti Historical Income Statement
MoonLake Stock Against Markets
MoonLake Immunotherapeuti Corporate Management
| Tino Anthamatten | Market Marketing | Profile | |
| Luciana Marques | People HR | Profile | |
| Jorge Silva | CEO CoFounder | Profile | |
| Nicolas Mosimann | General Counsel | Profile | |
| Oliver Daltrop | Chief Officer | Profile |
Additional Tools for MoonLake Stock Analysis
When running MoonLake Immunotherapeuti's price analysis, check to measure MoonLake Immunotherapeuti's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MoonLake Immunotherapeuti is operating at the current time. Most of MoonLake Immunotherapeuti's value examination focuses on studying past and present price action to predict the probability of MoonLake Immunotherapeuti's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MoonLake Immunotherapeuti's price. Additionally, you may evaluate how the addition of MoonLake Immunotherapeuti to your portfolios can decrease your overall portfolio volatility.